drugset
drugset / Trial / NCT05502549

A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of CB03-154 in Healthy Participants in Australia

NCT05502549 ↗

Phase 1 Completed 56 enrolled Shanghai Zhimeng Biopharma, Inc.
RandomizedSequentialQuadruple-blindTreatment

Summary

CB03-154 is an investigational drug developed by Shanghai Zhimeng Biopharma Inc. for the treatment of Epilepsy.

Timeline

Start
2022-11-29
Primary completion
2023-11-09
Completion
2023-12-15

Drugs

EvaluationDrugModalityDoseRoute
Subject CB03-154 Unknown 5 mg Oral
Subject CB03-154 Unknown 10 mg Oral
Subject CB03-154 Unknown 20 mg Oral
Subject CB03-154 Unknown 30 mg Oral
Subject CB03-154 Unknown 45 mg Oral

Indications

No indication recorded.